298 related articles for article (PubMed ID: 31851823)
21. Recapitulating the Binding Affinity of Nrf2 for KEAP1 in a Cyclic Heptapeptide, Guided by NMR, X-ray Crystallography, and Machine Learning.
Ortet PC; Muellers SN; Viarengo-Baker LA; Streu K; Szymczyna BR; Beeler AB; Allen KN; Whitty A
J Am Chem Soc; 2021 Mar; 143(10):3779-3793. PubMed ID: 33683866
[TBL] [Abstract][Full Text] [Related]
22. Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-protein interaction.
Wells G
Biochem Soc Trans; 2015 Aug; 43(4):674-9. PubMed ID: 26551711
[TBL] [Abstract][Full Text] [Related]
23. Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex.
Bello M; Morales-González JA
Int J Biol Macromol; 2017 Dec; 105(Pt 1):981-992. PubMed ID: 28746889
[TBL] [Abstract][Full Text] [Related]
24. Direct Keap1-kelch inhibitors as potential drug candidates for oxidative stress-orchestrated diseases: A review on In silico perspective.
Boyenle ID; Divine UC; Adeyemi R; Ayinde KS; Olaoba OT; Apu C; Du L; Lu Q; Yin X; Adelusi TI
Pharmacol Res; 2021 May; 167():105577. PubMed ID: 33774182
[TBL] [Abstract][Full Text] [Related]
25. Medicinal Chemistry Insights into the Development of Small-Molecule Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.
Zhao Z; Dong R; You Q; Jiang Z
J Med Chem; 2023 Jul; 66(14):9325-9344. PubMed ID: 37441735
[TBL] [Abstract][Full Text] [Related]
26. Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery.
Narayanan D; Tran KT; Pallesen JS; Solbak SMØ; Qin Y; Mukminova E; Luchini M; Vasilyeva KO; González Chichón D; Goutsiou G; Poulsen C; Haapanen N; Popowicz GM; Sattler M; Olagnier D; Gajhede M; Bach A
J Med Chem; 2022 Nov; 65(21):14481-14526. PubMed ID: 36263945
[TBL] [Abstract][Full Text] [Related]
27. Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides.
Karttunen M; Choy WY; Cino EA
J Phys Chem B; 2018 Jun; 122(22):5851-5859. PubMed ID: 29745220
[TBL] [Abstract][Full Text] [Related]
28. Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction.
Schaap M; Hancock R; Wilderspin A; Wells G
Protein Sci; 2013 Dec; 22(12):1812-9. PubMed ID: 24130096
[TBL] [Abstract][Full Text] [Related]
29. Emerging Screening Approaches in the Development of Nrf2-Keap1 Protein-Protein Interaction Inhibitors.
Leung CH; Zhang JT; Yang GJ; Liu H; Han QB; Ma DL
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31509940
[TBL] [Abstract][Full Text] [Related]
30. A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
Tran KT; Pallesen JS; Solbak SMØ; Narayanan D; Baig A; Zang J; Aguayo-Orozco A; Carmona RMC; Garcia AD; Bach A
J Med Chem; 2019 Sep; 62(17):8028-8052. PubMed ID: 31411465
[TBL] [Abstract][Full Text] [Related]
31. Advances in developing noncovalent small molecules targeting Keap1.
Barreca M; Qin Y; Cadot MEH; Barraja P; Bach A
Drug Discov Today; 2023 Dec; 28(12):103800. PubMed ID: 37852355
[TBL] [Abstract][Full Text] [Related]
32. Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) Inhibitors with High Metabolic Stability.
Lazzara PR; David BP; Ankireddy A; Richardson BG; Dye K; Ratia KM; Reddy SP; Moore TW
J Med Chem; 2020 Jun; 63(12):6547-6560. PubMed ID: 31682434
[TBL] [Abstract][Full Text] [Related]
33. ZJ01, a Small Molecule Inhibitor of the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction, Reduces Hyperoxic Acute Lung Injury in a Mouse Model.
Wan J; Lin S; Huang X; Li Q; Zeng L; Du S
Med Sci Monit; 2020 May; 26():e920467. PubMed ID: 32437336
[TBL] [Abstract][Full Text] [Related]
34. Discovery of Keap1-Nrf2 small-molecule inhibitors from phytochemicals based on molecular docking.
Li M; Huang W; Jie F; Wang M; Zhong Y; Chen Q; Lu B
Food Chem Toxicol; 2019 Nov; 133():110758. PubMed ID: 31412289
[TBL] [Abstract][Full Text] [Related]
35. Fragment-based drug discovery and its application to challenging drug targets.
Price AJ; Howard S; Cons BD
Essays Biochem; 2017 Nov; 61(5):475-484. PubMed ID: 29118094
[TBL] [Abstract][Full Text] [Related]
36. Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein-Protein Interaction Inhibitors with an Alternative Binding Mode.
Georgakopoulos N; Talapatra S; Dikovskaya D; Dayalan Naidu S; Higgins M; Gatliff J; Ayhan A; Nikoloudaki R; Schaap M; Valko K; Javid F; Dinkova-Kostova AT; Kozielski F; Wells G
J Med Chem; 2022 May; 65(10):7380-7398. PubMed ID: 35549469
[TBL] [Abstract][Full Text] [Related]
37. Discovery of disubstituted xylylene derivatives as small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction.
Abed DA; Lee S; Hu L
Bioorg Med Chem; 2020 Mar; 28(6):115343. PubMed ID: 32046917
[TBL] [Abstract][Full Text] [Related]
38. aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.
Tian L; Lu Y; Yang T; Deng Z; Xu L; Yao W; Ma C; Li X; Zhang J; Liu Y; Wang J
Redox Biol; 2019 Apr; 22():101149. PubMed ID: 30822690
[TBL] [Abstract][Full Text] [Related]
39. Design, Synthesis, and Structure-Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.
Zhou HS; Hu LB; Zhang H; Shan WX; Wang Y; Li X; Liu T; Zhao J; You QD; Jiang ZY
J Med Chem; 2020 Oct; 63(19):11149-11168. PubMed ID: 32902980
[TBL] [Abstract][Full Text] [Related]
40. KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease.
Dayalan Naidu S; Dinkova-Kostova AT
Open Biol; 2020 Jun; 10(6):200105. PubMed ID: 32574549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
